关键词: Roche 纤维化 Galapagos
2013年3月9日讯 /生物谷BIOON/ --瑞士制药巨头Roche公司宣布,退出与比利时制药公司Galapagos公司在纤维化领域的合作协议。而按照协议Roche公司也将向Galapago公司支付575万欧元使得Galapago在该项目上的资金总额达到1600万欧元。
近年来纤维化疾病研究领域一直是各大医药公司的研究热点,Biogen、Bristol-Myers Squibb 和Novartis都在其中投入巨大精力。(生物谷Bioon.com)
详细英文报道:
Swiss drug giant Roche ($RHHBY) has exited an alliance with Belgium-based biotech Galapagos that focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases. On its way out, Roche is forking over €5.75 million to Galapagos for the biotech's efforts through 2012, increasing the total payments from the alliance to €16 million, according to the company. "We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, CEO of Galapagos, in a statement. Fibrotic diseases such as pulmonary fibrosis have been a hot area of drug development among biopharma players, including Biogen Idec ($BIIB), Bristol-Myers Squibb ($BMY) and Novartis ($NVS). There are no approved treatments for idiopathic pulmonary fibrosis in the U.S.
(责任编辑:yan.mao)